

# Palliative care for patients with irresectable or recurrent cancer of the upper gastrointestinal tract: a randomized study

<b>Submission date</b> 19/07/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 19/07/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 08/01/2021	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr P.D. Siersema

**Contact details**  
Erasmus MC - University Medical Center Rotterdam  
Department of Gastroenterology and Hepatology  
Room HS 512  
P.O. Box 2040  
Rotterdam  
Netherlands  
3000 CA  
+31 (0)10 4632748  
p.siersema@erasmusmc.nl

## Additional identifiers

**Protocol serial number**  
MEC-2005-176, NL628, NTR687

## Study information

**Scientific Title**

Palliative care for patients with irresectable or recurrent cancer of the upper gastrointestinal tract: a randomized study

**Acronym**

PACT study.

**Study objectives**

Does nurse-led follow-up at home lead to improved quality of life and satisfaction and a reduction in costs compared to medical follow-up at the outpatient clinic, without compromising the medical condition of patients?

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled, parallel group trial

**Primary study design**

Interventional

**Study type(s)**

Quality of life

**Health condition(s) or problem(s) studied**

Esophageal, pancreatic or hepatobiliary cancer

**Interventions**

Nurse-led follow-up at home at two-weekly and later monthly intervals until month 13 or death versus medical follow-up at the outpatient clinic at one month and thereafter every two months until month 13 or death

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Quality of life questionnaires

**Key secondary outcome(s)**

Patient satisfaction (questionnaire) costs

**Completion date**

01/01/2009

# Eligibility

## Key inclusion criteria

1. Patients with irresectable or recurrent esophageal cancer, pancreatic cancer or hepatobiliary cancer, for whom no curative treatment options are available
2. Informed consent

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Sex

All

## Key exclusion criteria

1. Not able to understand or read the Dutch language
2. Undergoing treatment with chemotherapy or radiotherapy or a combination

## Date of first enrolment

01/06/2006

## Date of final enrolment

01/01/2009

# Locations

## Countries of recruitment

Netherlands

## Study participating centre

Erasmus MC - University Medical Center Rotterdam

Rotterdam

Netherlands

3000 CA

# Sponsor information

## Organisation

Health Care Research Program Erasmus MC 2003 (The Netherlands)

# Funder(s)

## Funder type

University/education

## Funder Name

Erasmus Medical Center

## Alternative Name(s)

Erasmus Medical Center, Erasmus MC, Erasmus Universitair Medisch Centrum, Erasmus University Medical Center, Universitair Medisch Centrum Rotterdam, Erasmus Universitair Medisch Centrum Rotterdam, EMC

## Funding Body Type

Government organisation

## Funding Body Subtype

Universities (academic only)

## Location

Netherlands

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/03/2014	08/01/2021	Yes	No